انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
#24 – Scaling up in Biotech, Raising $300M for a Single Pharma Product | Mark Hahn
Manage episode 379553432 series 2940551
Successful biotech companies require a capable CFO to guide the company through conducting clinical trials, securing regulatory approvals, establishing scalable production, and adeptly conveying value to healthcare stakeholders.
Mark Hahn is a seasoned executive with over 25 years of CFO experience. He is currently the CFO of Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
In this episode, Hercules Capital’s Janice Bourque is joined by Hahn to discuss his experience as CFO of Verona, Dova, and Cempra, the intricacies of single-asset companies, preparing a company for FDA approval and commercialization, identifying a successful launch, and much more.
Topics Include:
- Mark’s experience as CFO of Verona, Dova, and Cempra
- The intricacies of single-asset companies and the challenges when raising capital
- The steps a CFO should take when preparing for FDA approval and commercialization
- What biotech companies should focus on before presenting to the FDA
- How to know when you’ve had a successful launch
- Mark’s experience as a CFO with a late-stage asset
- And other topics…
Mark Hahn is a seasoned CFO with over 25 years of experience. He joined Verona Pharma as CFO in 2020. Prior to Verona, Hahn served as CFO of Dova Pharmaceuticals through its 2019 acquisition by Swedish Orphan Biovitrum for $915 million. There, he was instrumental in raising capital and launching the company’s first commercial product. Prior to Dova, Hahn was CFO of Cempra, where he led the company’s IPO and several subsequent follow-on offerings until the company’s acquisition by Melinta Therapeutics in 2017. Earlier, Hahn was the CFO of several other public and private companies. Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.
37 حلقات
Manage episode 379553432 series 2940551
Successful biotech companies require a capable CFO to guide the company through conducting clinical trials, securing regulatory approvals, establishing scalable production, and adeptly conveying value to healthcare stakeholders.
Mark Hahn is a seasoned executive with over 25 years of CFO experience. He is currently the CFO of Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.
In this episode, Hercules Capital’s Janice Bourque is joined by Hahn to discuss his experience as CFO of Verona, Dova, and Cempra, the intricacies of single-asset companies, preparing a company for FDA approval and commercialization, identifying a successful launch, and much more.
Topics Include:
- Mark’s experience as CFO of Verona, Dova, and Cempra
- The intricacies of single-asset companies and the challenges when raising capital
- The steps a CFO should take when preparing for FDA approval and commercialization
- What biotech companies should focus on before presenting to the FDA
- How to know when you’ve had a successful launch
- Mark’s experience as a CFO with a late-stage asset
- And other topics…
Mark Hahn is a seasoned CFO with over 25 years of experience. He joined Verona Pharma as CFO in 2020. Prior to Verona, Hahn served as CFO of Dova Pharmaceuticals through its 2019 acquisition by Swedish Orphan Biovitrum for $915 million. There, he was instrumental in raising capital and launching the company’s first commercial product. Prior to Dova, Hahn was CFO of Cempra, where he led the company’s IPO and several subsequent follow-on offerings until the company’s acquisition by Melinta Therapeutics in 2017. Earlier, Hahn was the CFO of several other public and private companies. Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.
37 حلقات
كل الحلقات
×![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #36 - Building the Super App for Mealtime: Wonder's Recipe for Disrupting Meal Delivery | Kelley Morrell 46:16
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #35 - Revolutionizing Compliance: AI's Role in Modern Finance | Erkin Adylov 35:51
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #34 - The Evolution of Biotech Deals: From Pharma Consolidation to Innovation | Stephen Sands 47:03
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #33 - How Corporate Venture Capital is Driving Healthcare Innovation | Vijay Patel 57:04
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #32 - The Future of Drug Affordability and Access | Peter Kolchinsky 56:46
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #31 - Dynamics of Venture Debt: Balancing Legal and Business Objectives | David Ephraim 26:57
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #30 – Rise of the Business Operator: Cultivating the Ultimate Community of Tech Leaders | Casey Woo 50:50
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #29 – Endpoints News: Predictions for Biotech in 2024 and Beyond | John Carroll 46:00
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #28 – The Non-CFO, CFO: Executive Leadership, Acquisitions, and Serving 350 Million Users as Fandom’s CFO | Ed Lu 56:53
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #27 – The Evolution of Biotech: Lessons From 35 Years of Early Stage Investing | Terry McGuire 34:29
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #26 – Biotech and the Public: Breakthroughs, Drug Prices, and Public Relations | Rich Aldrich 40:59
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #25 – From Physician to Founder: Scaling Iora Health to a $2 Billion Exit | Rushika Fernandopulle 33:19
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #24 – Scaling up in Biotech, Raising $300M for a Single Pharma Product | Mark Hahn 31:57
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #23 – From $3B to $29B in 7 Years, the Boom in Healthcare Technology Investment | Michael Greeley 28:48
![Ventured Growth with Hercules Capital podcast artwork](/static/images/64pixel.png)
1 #22 – Women’s Health: An Overlooked Market That’s Hot for Investors in 2023 | Elizabeth Bailey 32:39
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.